hVIVO Reports Interim Results and Anticipates Growth in 2026

hVIVO plc (LSE:HVO) has published its interim results for H1 2025, reporting revenue of £24.2 million, in line with full-year expectations. While both revenue and EBITDA declined compared to the previous year, the company remains optimistic about returning to growth in 2026.

The integration of recent acquisitions, CRS and Cryostore, is nearing completion, and sales synergies are starting to materialize. Key contracts secured include a £3.2 million hLAB agreement and a letter of intent for a major Phase III human challenge trial. Early signs from the company’s diversification strategy are positive, with a strong sales pipeline and new service lines contributing to future growth prospects. Management expects high-single-digit revenue growth in 2026 as market conditions normalize.

The outlook reflects solid financial performance and attractive valuation metrics, including a low P/E ratio and steady revenue growth. However, technical analysis points to some bearish trends, slightly tempering the overall assessment. Recent corporate events were not factored into the score but provide additional optimism for the company’s trajectory.

About hVIVO plc

hVIVO is a full-service early-phase Contract Research Organisation (CRO) and a global leader in human challenge trials. The company provides end-to-end clinical development services to biopharma clients, specializing in infectious and respiratory disease trials. It operates the largest quarantine facility in London and offers laboratory services under the hLAB brand. Through subsidiaries CRS and Venn Life Sciences, hVIVO delivers early-phase clinical trial services and consulting to the biopharma sector.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.